News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Lee's Pharmaceutical Obtains China Rights to Therapeutic Peptide from RegeneRx Biopharmaceuticals, Inc. (RGRX)


7/17/2012 11:00:55 AM

July 16, 2012 -- Lee’s Pharmaceutical of Hong Kong has bought the China rights to a novel clinical-stage peptide from RegeneRx Biopharma. Thymosin beta 4 (Tß4) is being developed by for tissue and organ protection, repair and regeneration. Its three formulations target very different indications: dry eye, cardiovascular/nervous system disorders, and skin disease/chronic wounds. More details....

Stock Symbols: (HK: 950) (OTCBB: RGRX)


Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES